Wright Weighs in on New HHS Advisory Approving Medication Management Pilot
December 13, 2017
FierceHealthcare
Special Counsel Jill Wright is quoted in a FierceHealthcare article, “OIG Approves Medication Management Pilot, Offering Hints at How it Will Regulate Data-Sharing Partnerships,” about a new advisory opinion by the Department of Health and Human Services’ Office of Inspector General approving of a medication management pilot.
Wright said the opinion, while limited to the circumstances described in the advisory, offers a framework for collaborations that rely on real-time data-sharing among multiple industry partners. “It shows the industry that when sufficient safeguards are included in the structure of innovative partnerships, OIG will find that they pose a low risk under the Anti-Kickback Statute,” she said.
Wright said the opinion, while limited to the circumstances described in the advisory, offers a framework for collaborations that rely on real-time data-sharing among multiple industry partners. “It shows the industry that when sufficient safeguards are included in the structure of innovative partnerships, OIG will find that they pose a low risk under the Anti-Kickback Statute,” she said.
Related News
March 13, 2026
In the News
Chris Babcock and Chris Converse on Wave of Companies Moving to Texas
Foley & Lardner LLP partners Chrisopher Babcock and Chris Converse commented on the widening trend of companies reincorporating to Texas in the Houston Business Journal article, “Texas law changes could spark wave of corporate redomestication proposals."
March 12, 2026
In the News
Louis Lehot Explores M&A's Growing Blitzhire Phenomenon
Foley & Lardner LLP partner Louis Lehot authors article on the emergence of blitzhires in the Mergers & Acquisitions article, “Blitzhires: The New Fast-Moving M&A Deal.”
March 10, 2026
In the News
Aaron Maguregui Shares Insights on Shadow AI Risks in Health Care
Foley & Lardner LLP partner Aaron Maguregui was quoted in the Part B News article, “Do you need AI policy? Experts suggest guardrails as 'shadow AI' spreads,” discussing the emerging risks of unsanctioned 'shadow AI' use by clinicians and the need to establish robust AI governance.